Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zevalin Consolidation vs Rituximab Maintenance in Follicular Lymphoma
NCT01662102Phase 3Terminated
- Sponsor
- Spectrum Pharmaceuticals, Inc.
- Start
- Dec 2012
- Primary completion
- Mar 2013
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ibritumomab tiuxetan in follicular lymphoma (FL) (2 arms), sponsored by Spectrum Pharmaceuticals, Inc. Primary endpoint: Progression Free Survival at 2.7 months. Started Dec 2012; status: terminated.
02
Drugs
ibritumomab tiuxetan
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT01662102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01662102.